Literature DB >> 10837397

Matrix metalloproteinase biology applied to vitreoretinal disorders.

C S Sethi1, T A Bailey, P J Luthert, N H Chong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10837397      PMCID： PMC1723500          DOI： 10.1136/bjo.84.6.654

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  159 in total

1.  Physiological mechanisms for metalloproteinase activation.

Authors:  G Murphy; R Ward; J Gavrilovic; S Atkinson
Journal:  Matrix Suppl       Date:  1992

2.  Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid.

Authors:  J A Vranka; E Johnson; X Zhu; A Shepardson; J P Alexander; J M Bradley; M K Wirtz; R G Weleber; M L Klein; T S Acott
Journal:  Curr Eye Res       Date:  1997-02       Impact factor: 2.424

3.  Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies.

Authors:  U Felbor; D Doepner; U Schneider; E Zrenner; B H Weber
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-05       Impact factor: 4.799

4.  Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors.

Authors:  G G Garzetti; A Ciavattini; G Lucarini; A Pugnaloni; M De Nictolis; S Amati; C Romanini; G Biagini
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

Review 5.  Matrix metalloproteinase inhibition. From the Jurassic to the third millennium.

Authors:  J F Woessner
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

Review 6.  Matrix metalloproteinase inhibitors.

Authors:  P D Brown
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

7.  Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.

Authors:  A E Kossakowska; D R Edwards; S S Lee; L S Urbanski; A L Stabbler; C L Zhang; B W Phillips; Y Zhang; S J Urbanski
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

8.  Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation.

Authors:  K P Langton; M D Barker; N McKie
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

9.  Gelatinase B modulates selective opening of the blood-brain barrier during inflammation.

Authors:  S Mun-Bryce; G A Rosenberg
Journal:  Am J Physiol       Date:  1998-05

10.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.

Authors:  D R Edwards; G Murphy; J J Reynolds; S E Whitham; A J Docherty; P Angel; J K Heath
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598
View more
  19 in total

1.  Is granuloma annulare related to intermediate uveitis with retinal vasculitis?

Authors:  B van Kooij; M Canninga van Dijk; J de Boer; V Sigurdsson; A Rothova
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Effects of doxycycline on intestinal ischemia reperfusion injury induced by abdominal compartment syndrome in a rat model.

Authors:  N Fatih Yaşar; Riza Ozdemir; Enver Ihtiyar; Nilüfer Erkasap; Tülay Köken; Murat Tosun; Setenay Oner; Serdar Erkasap
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

3.  Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment.

Authors:  Chrysanthos Symeonidis; Eudoxia Diza; Eleni Papakonstantinou; Efimia Souliou; George Karakiulakis; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-29       Impact factor: 3.117

4.  Vitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.

Authors:  Rob J Van Geest; Ingeborg Klaassen; Sarit Y Lesnik-Oberstein; H Stevie Tan; Marco Mura; Roel Goldschmeding; Cornelis J F Van Noorden; Reinier O Schlingemann
Journal:  J Cell Commun Signal       Date:  2012-10-02       Impact factor: 5.782

5.  Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome.

Authors:  S L Ho; G F Dogar; J Wang; J Crean; Q D Wu; N Oliver; S Weitz; A Murray; P E Cleary; C O'Brien
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

6.  Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Authors:  Chrysanthos Symeonidis; Eleni Papakonstantinou; Asimina Galli; Ioannis Tsinopoulos; Asimina Mataftsi; Spyridon Batzios; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-20       Impact factor: 3.117

7.  Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.

Authors:  Mohammed El Bradey; Lingyun Cheng; Dirk-Uwe Bartsch; Krzystof Appelt; Nuttawut Rodanant; Germaine Bergeron-Lynn; William R Freeman
Journal:  J Ocul Pharmacol Ther       Date:  2004-06       Impact factor: 2.671

8.  Transcription Factors Pax6 and AP-2alpha Interact To Coordinate Corneal Epithelial Repair by Controlling Expression of Matrix Metalloproteinase Gelatinase B.

Authors:  Jeremy M Sivak; Judith A West-Mays; Amy Yee; Trevor Williams; M Elizabeth Fini
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

9.  Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy.

Authors:  Anna B Kłysik; Julia Naduk-Kik; Zbigniew Hrabec; Roman Goś; Elżbieta Hrabec
Journal:  Arch Med Sci       Date:  2010-06-30       Impact factor: 3.318

10.  Polymorphisms in matrix metalloproteinases MMP1 and MMP9 are associated with primary open-angle and angle closure glaucoma in a Pakistani population.

Authors:  Shazia Micheal; Sajeela Yousaf; Muhammad Imran Khan; Farah Akhtar; Farah Islam; Wajid Ali Khan; Anneke I den Hollander; Raheel Qamar; Asifa Ahmed
Journal:  Mol Vis       Date:  2013-02-20       Impact factor: 2.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.